Doctors are ready to bring a medical breakthrough to patients in Wisconsin.
The FDA recently approved the use of a gene-editing tool by CRISPR Therapeutics to treat long-overlooked genetic disorders like Sickle Cell Disease.
Officials at Children’s Wisconsin say the Casgevy treatment can modify a patient’s own stem cells so they are no longer producing sickle cells — which can cause health complications and lead to early death.
The MACC Fund Center for Cancer and Blood Disorders at Children’s Wisconsin is now offering the newly FDA-approved Casgevy therapy to children 12 years and older who have severe sickle cell disease or transfusion-dependent thalassemia.
Watch: ‘Crucial and wonderful:’ Patients React to Sickle Cell Treatment’s WI Debut
Sickle Cell Warriors react to new treatment coming to Wisconsin
TMJ4 Lighthouse Team Reporter Ryan Jenkins goes in-depth, talking to neighbors throughout Milwaukee who are impacted by Sickle Cell Disease in various ways about what this new medical advancement means to them.